Gueguen 2021 Methods Mol Biol

Gueguen N, Lenaers G, Reynier P, Weissig V, Edeas M (2021) Mitochondrial dysfunction in mitochondrial medicine: current limitations, pitfalls, and tomorrow. https://doi.org/10.1007/978-1-0716-1266-8_1

» Methods Mol Biol 2276:1-29. PMID: 34060029

Gueguen Naig, Lenaers Guy, Reynier Pascal, Weissig Volkmar, Edeas Marvin (2021) Methods Mol Biol

Abstract: Until recently restricted to hereditary mitochondrial diseases, mitochondrial dysfunction is now recognized as a key player and strategic factor in the pathophysiological of many human diseases, ranging from the metabolism, vascular, cardiac, and neurodegenerative diseases to cancer. Because of their participation in a myriad of cellular functions and signaling pathways, precisely identifying the cause of mitochondrial "dysfunctions" can be challenging and requires robust and controlled techniques. Initially limited to the analysis of the respiratory chain functioning, these analytical techniques now enlarge to the analyses of mitochondrial and cellular metabolism, based on metabolomic approaches.Here, we address the methods used to assay mitochondrial dysfunction, with a highlight on the techniques used in diagnosis on tissues and cells derived from patients, the information they provide, and their strength and weakness. Targeting mitochondrial dysfunction by various strategies is a huge challenge, requires robust methods of evaluation, and should be able to take into consideration the mitochondria dynamics and localization. The future of mitochondrial medicine is strongly related to a perfect comprehension of its dysfunction. • Keywords: Bioenergetics, Devices, Metabolomics, Mitochondria evaluation, Mitochondrial dysfunctions • Bioblast editor: Plangger M • O2k-Network Lab: FR Angers Gueguen N

Labels: MiParea: Instruments;methods, mt-Medicine, Patients 

Stress:Mitochondrial disease 

2023-04